Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants.
Front Immunol
; 14: 1111385, 2023.
Article
in En
| MEDLINE
| ID: mdl-36895554
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Front Immunol
Year:
2023
Document type:
Article
Affiliation country: